When no one wamted to partner AXAL because the clincial data wasn't strong enough, NEO was billed ADXS' next gen (i.e. last hope). That all changed when Amgen saw the initial data and bailed. Hence the company's platform is valued very little for valid reasons, not because of hedge funds or manulipulation but be cause of lack of interest and demand for the platform.
News 
Market Data 
Discover 
